Total Funding
72
62
Total FundingVenture - Series Unknown raised
Growth Score
-7 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
27557
Napo Pharmaceuticals develops and commercializes proprietary pharmaceuticals in collaboration with local partners.
Acquired by 
Jaguar Health
Pravin Chaturvedi: Chief Scientific OfficerPast Role: IndUS Pharmaceuticals, Chief Executive Officer
Lisa Conte: Founder & CEO
Jaguar Health
About the Company
Napo Pharmaceuticals, Inc. develops and commercializes proprietary pharmaceuticals for international markets. It offers Crofelemer for gastrointestinal indications, including chronic diarrhea in persons living with HIV/AIDS; and NP-500, a product for insulin-resistant diseases. The company also provides CRO-IBS for diarrhea-predominant IBS;
CRO-HIV for AIDS-related diarrhea; CRO-ID for acute infectious diarrhea; and CRO-PED for pediatric diarrhea. It offers its products for D-IBS, HIV, acute-cholera, and pediatric markets. The company was founded in 2001 and is based in San Francisco, California. It has a subsidiary location in Mumbai, India.
Women Founded
Women Led
